Home › Cases › Brain Metastases — Raised ICP
Brain Metastases
Brain Metastases — Raised ICP
6 questions
Question 1 · Recognition
Correct answer: Raised intracranial pressure from brain metastases — the combination of morning headache, vomiting, focal neurology, and papilloedema is the classic presentation
Why
Raised intracranial pressure (ICP) from brain metastases classically presents with the triad of: morning headache (worse on waking — due to nocturnal CO₂ retention causing cerebral vasodilation), vomiting (often without nausea — due to direct medullary compression), and focal neurological deficits (site-dependent). Papilloedema on fundoscopy (blurring of optic disc margins, loss of venous pulsations, flame haemorrhages) confirms raised ICP — it takes days to weeks to develop, so its absence does not exclude acute raised ICP. In a patient with known metastatic breast cancer, brain metastases are the most likely cause until proven otherwise. This presentation requires urgent neuroimaging.
Key point
Morning headache + vomiting + focal neurology + papilloedema = raised ICP — in a cancer patient, brain metastases must be excluded urgently.
Question 2 · Imaging
Correct answer: Urgent CT head without contrast first; if negative but clinical suspicion remains high, proceed to contrast-enhanced MRI brain
Why
Urgent CT head (without contrast first, then with contrast) is the standard initial investigation for suspected raised ICP, as it is widely available, fast, and can identify haemorrhage, oedema, mass effect, and hydrocephalus. CT detects brain metastases >1 cm but may miss small lesions. Contrast-enhanced MRI brain is the gold standard for brain metastases (sensitivity >95%) and should follow if CT is normal but clinical suspicion remains high, or for surgical planning. Skull XR has no role in suspected intracranial metastases. Lumbar puncture is absolutely contraindicated when raised ICP is suspected due to risk of tonsillar herniation (coning) — LP should only be performed after neuroimaging excludes a mass lesion causing midline shift or hydrocephalus.
Key point
Urgent CT head first for suspected raised ICP — LP is contraindicated until imaging excludes mass lesion; MRI is gold-standard for brain metastases.
Question 3 · Immediate Management — Dexamethasone
Correct answer: Dexamethasone 8mg BD (orally or IV) to reduce peri-tumoural oedema; prescribe with a proton pump inhibitor
Why
Dexamethasone is the corticosteroid of choice for peri-tumoural cerebral oedema in brain metastases. Standard dose is 8 mg BD (morning and noon to avoid insomnia), though 16 mg/day or higher may be used acutely. It reduces vasogenic oedema by restoring blood-brain barrier integrity, typically producing clinical improvement within 24–72 hours. Always co-prescribe a proton pump inhibitor (PPI) to prevent steroid-induced gastric ulceration. Crucially, dexamethasone is NOT routinely recommended for primary brain tumours (gliomas) — in glioblastoma, steroids reduce cerebral oedema transiently but are associated with worse outcomes and immunosuppression when used long-term; they are used only when symptomatic from oedema. Mannitol is reserved for acute herniation/coning, not routine management.
Key point
Dexamethasone 8mg BD reduces peri-tumoural oedema in brain metastases — always add a PPI; not routinely indicated in primary brain tumours (gliomas).
Question 4 · Seizure Management
Correct answer: Start levetiracetam 500mg BD, titrated to 1000–1500mg BD — first-line AED for brain tumour-related epilepsy with a favourable drug interaction profile
Why
Levetiracetam is the preferred first-line anti-epileptic drug (AED) for seizures related to brain tumours and metastases, as recommended by NICE and the British Epilepsy Association. Starting dose is typically 500 mg BD, titrated to 1000–1500 mg BD. Key advantages: minimal hepatic enzyme induction (important as many chemotherapy agents are CYP450-metabolised), no significant interaction with dexamethasone, available IV for patients who cannot swallow. Phenytoin is now avoided in this context — it is a potent CYP450 inducer (reducing chemotherapy efficacy), has complex pharmacokinetics, and multiple drug interactions with steroids and cytotoxics. Prophylactic AEDs are not recommended in patients who have not had a seizure.
Key point
Levetiracetam is first-line for brain tumour-related epilepsy — avoid phenytoin due to CYP450 induction reducing chemotherapy efficacy.
Question 5 · MDT Approach — Treatment Options
Correct answer: Stereotactic Radiosurgery (SRS) to all 3 lesions ± surgical resection of the largest — preferred over WBRT for oligometastatic disease with good performance status
Why
Management of brain metastases is stratified by number of lesions, systemic disease control, and performance status. For oligometastatic disease (1–4 lesions) with good performance status and controlled systemic disease, Stereotactic Radiosurgery (SRS) is now preferred over WBRT — it delivers high-dose radiation precisely to lesions with lower toxicity to surrounding brain, preserving neurocognitive function. Surgical resection is considered for the largest/most symptomatic lesion, particularly if histological confirmation is needed. WBRT remains an option for multiple lesions, leptomeningeal disease, or poor performance status but causes significant neurocognitive decline. Breast cancer brain metastases may also respond to HER2-targeted agents (e.g., trastuzumab emtansine, tucatinib, lapatinib) that penetrate the blood-brain barrier.
Key point
Oligometastatic brain disease + good performance status = Stereotactic Radiosurgery (SRS) preferred over WBRT to preserve neurocognitive function.
Question 6 · Prognosis and Advance Care Planning
Correct answer: Engage honestly using prognostic tools (e.g., GRADED PROGNOSTIC ASSESSMENT — GPA), explore what she understands, what she wants to know, and initiate advance care planning including ReSPECT form
Why
Honest, compassionate prognostic communication is a core oncology competency. The Graded Prognostic Assessment (GPA) and disease-specific GPA (DS-GPA) tools estimate prognosis in brain metastases based on age, KPS, extracranial metastases, and number of brain lesions — breast GPA includes molecular subtype (HER2+ has the best prognosis). The consultation should use 'ask-tell-ask' communication: explore what she already understands, gauge how much information she wants, and respond accordingly. Advance care planning should include: ReSPECT (Recommended Summary Plan for Emergency Care and Treatment) form, preferred place of care and death, and referral to palliative care for symptom management. Avoid giving precise survival times — wide confidence intervals make them misleading and distressing.
Key point
Use the GPA tool for prognosis in brain metastases and initiate advance care planning including a ReSPECT form — use ask-tell-ask communication, avoid giving fixed survival estimates.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.